BTG plc (BTG) Earns “Buy” Rating from Deutsche Bank AG

BTG plc (LON:BTG)‘s stock had its “buy” rating reaffirmed by stock analysts at Deutsche Bank AG in a report released on Friday. They currently have a GBX 775 ($10.19) price objective on the stock. Deutsche Bank AG’s price objective would suggest a potential upside of 9.54% from the stock’s previous close.

A number of other equities analysts have also recently issued reports on BTG. J P Morgan Chase & Co reiterated a “neutral” rating on shares of BTG plc in a report on Friday, October 6th. Numis Securities Ltd reiterated a “buy” rating and set a GBX 900 ($11.83) price objective on shares of BTG plc in a report on Wednesday, August 9th. Peel Hunt reiterated a “hold” rating and set a GBX 680 ($8.94) price objective on shares of BTG plc in a report on Wednesday, September 20th. Stifel Nicolaus reiterated a “buy” rating and set a GBX 800 ($10.52) price objective on shares of BTG plc in a report on Wednesday, August 30th. Finally, Shore Capital reiterated a “not rated” rating on shares of BTG plc in a report on Thursday, July 13th. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of GBX 780.33 ($10.26).

ILLEGAL ACTIVITY NOTICE: “BTG plc (BTG) Earns “Buy” Rating from Deutsche Bank AG” was first reported by Markets Daily and is owned by of Markets Daily. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://www.themarketsdaily.com/2017/10/13/btg-plc-btg-earns-buy-rating-from-deutsche-bank-ag.html.

About BTG plc

BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.

Analyst Recommendations for BTG plc (LON:BTG)

Receive News & Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply